Salirasib is primarily investigated for its potential in cancer therapy, particularly targeting tumors driven by Ras protein signaling. It functions by interfering with the membrane localization of Ras, a critical step for its activation, thereby inhibiting downstream pathways involved in cell proliferation and survival. This makes Salirasib a candidate for treating cancers where Ras mutations are prevalent, such as pancreatic, lung, and colorectal cancers. Preclinical studies have shown that Salirasib can reduce tumor growth and enhance the effectiveness of other anticancer agents. Its application is mainly in experimental and clinical research settings, focusing on developing targeted therapies with improved specificity and reduced side effects compared to conventional chemotherapy.